Climb Bio Inc. Ordinary Shares CLYM 深 沪
等待开盘 08-06 09:30:00 美东时间
1.74
+0.040
+2.35%
华盛通- 最 高1.85
- 今 开1.75
- 成交量 126.86万股
- 最 低 1.68
- 昨 收 1.70
- 总市值 1.18亿
- 52周最高 8.79
- 市盈率 静 --
- 换手率 1.88%
- 52周最低 1.05
- 委 比 -60.08%
- 总股本 6757.58万
- 历史最高 29.69
- 量 比 1.18
- 振 幅 10.00%
- 历史最低 1.05
- 每 手 1
- 风险率 2.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
Climb Bio appoints Dr. Edgar Charles as CMO and Cindy Driscoll as Senior Vice President, Finance. Dr. Charles brings over 20 years of experience in immunology-focused drug development, while Cindy has extensive financial leadership in biotech. Their expertise strengthens Climb Bio’s clinical programs for immune-mediated diseases, including budoprutug and CLYM116. Both executives received equity awards as part of their inducement packages.
06-18 11:00
美股大行评级 | 潜在涨幅925.64%！Aemetis获Ascendiant Capital升目标价至20美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1138028221594226688.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从19美元升至20美元</p> <p>• Ascendiant Capital：维持Lucid Diagnostics(LUCD)"买
06-07 08:37
Oppenheimer Initiates Coverage On Climb Bio with Outperform Rating, Announces Price Target of $10
Oppenheimer analyst Leland Gershell initiates coverage on Climb Bio (NASDAQ:CLYM) with a Outperform rating and announces Price Target of $10.
06-07 01:10
Climb Bio GAAP EPS of -$0.31
Climb Bio press release (NASDAQ:CLYM): Q1 GAAP EPS of -$0.31. Cash Position: Cash, cash equivalents and marketable securities were $197.8 million as of March 31, 2025. Cash, cash equivalents and marke...
05-14 21:53
Climb Bio Q1 EPS $(0.31) Misses $(0.15) Estimate
Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.15) by 106.67 percent. This is a 416.67 percent decrease over losses of $(0.06) per share from the
05-14 19:12
Climb Bio Expands Board with New Director Appointments
The latest update is out from Climb Bio ( ($CLYM) ). On March 27, 2025, Climb B...
04-01 19:28
Climb Bio Advances Clinical Trials and Expands Pipeline
Climb Bio, Inc. ( ($CLYM) ) has released its Q4 earnings. Here is a breakdown o...
03-27 12:01
Eliem Therapeutics GAAP EPS of -$0.13 beats by $0.02
Eliem Therapeutics press release (NASDAQ:CLYM): Q4 GAAP EPS of -$0.13 beats by $0.02. Cash, cash equivalents and marketable securities were $212.5 million as of December 31, 2024, as compared to $106....
03-26 04:38
Climb Bio Expects Cash Runway Through 2027
Cash, cash equivalents and marketable securities were $212.5 million as of December 31, 2024, as compared to $106.8 million as of December 31, 2023.
03-26 04:10
Top-rated biotechs with negative enterprise values
After four consecutive years of underperformance, biotech stocks are among the most unloved segments in the market. Major industry benchmarks SPDR S&P Biotech ETF (NYSEARCA:XBI) and the iShares Biotec...
03-02 03:28
